explore -WSS

explore

author：comprehensive 2025-09-28 00:49:03 - browse：66

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

focus

WSS

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

California man arrested in connection with serial murders of Mexican strip club workers

Illumina board agrees to spin off Grail, as divestment plans proceed

CMS got Medicare Advantage quality rating wrong, judge rules

Sen. Bill Cassidy on how to lower drug prices

focus

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

ASCO Daily Recap: CAR

BioMarin wins approval for gene therapy to treat hemophilia A

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

How one medical school became remarkably diverse

Elevance PBM president out as customers face prescription chaos

Walensky prepares to leave CDC — and Congress — behind

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

focus

Illumina board agrees to spin off Grail, as divestment plans proceed

Illumina board agrees to spin off Grail, as divestment plans proceed

How CO2 helps viruses stay alive longer in the air

Structure Therapeutics oral GLP

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Another man arrested in connection with shooting at Kansas nightclub

focus

knowledge

Wikipedia

Wikipedia